GlassScriptPhysician profile
Lina Leykina
NPI 1689817363
$16,290.34
in general payments reported to CMS, 2019-2025
62 companies · $3,597 in 2025
The $3,597 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,648 · 2020: $1,628 · 2021: $1,053 · 2022: $2,682 · 2023: $2,501 · 2024: $2,181 · 2025: $3,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,833 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,435 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,832.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,435.00 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,148.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $1,803.41 | 2019-2025 | Korlym |
| Medtronic, INC. | $1,424.10 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Astrazeneca Pharmaceuticals LP | $1,067.11 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $888.10 | 2021-2025 | |
| Amgen INC. | $852.61 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $809.13 | 2020-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $797.97 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $770.80 | 2019-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amneal Pharmaceuticals LLC | $750.15 | 2019-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.85 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $482.98 | 2019-2025 | |
| Insulet Corporation | $449.69 | 2019-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $374.78 | 2019-2023 | Verquvo, Steglatro |
| Abbvie INC. | $370.91 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Leykina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.